-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group Ranked Among the Top 10 in the 2023 China Chemical Pharmaceutical R&D Strength Ranking
Category:
发布时间：2023-06-16
【概要描述】
Bringing together top talent from all quarters to chart the course for industrial development. On June 16, the 2023 High-Quality Development Conference on the Greater Health Industry and the 8th China Pharmaceutical R&D Innovation Summit, co-hosted by Yaozhi Network and the editorial board of China Pharmaceutical News, were held in the mountain city of Chongqing. At the opening ceremony of the summit, the 2023 China Pharmaceutical R&D Strength Ranking series was officially unveiled, with Shijiazhuang Sihua Pharmaceutical Group named among the Top 30 in the 2023 China Comprehensive Pharmaceutical R&D Strength Ranking and the Top 10 in the 2023 China Chemical Drug R&D Strength Ranking. Qu Jiguang, Chairman of the Group’s Board of Directors, was honored as the 2023 China Pharmaceutical Innovation Leader.
Bringing together top talent from across the country to drive industrial development. On June 16, the 2023 High-Quality Development Conference for the Greater Health Industry and the 8th China Pharmaceutical R&D and Innovation Summit, co-hosted by Yaozhi Network and the editorial board of China Pharmaceutical News, were held in the mountain city of Chongqing. At the opening ceremony of the summit, the 2023 China Pharmaceutical R&D Strength Rankings were officially unveiled, with Shijiazhuang Sihua Pharmaceutical Group named among the Top 30 in the 2023 China Overall Pharmaceutical R&D Strength Ranking and the Top 10 in the 2023 China Chemical Pharmaceutical R&D Strength Ranking. Qu Jiguang, Chairman of the Group’s Board of Directors, was honored as the 2023 China Pharmaceutical Innovation Leader.
According to reports, the “2023 China Pharmaceutical R&D Strength Ranking” was compiled by Yaoshi Network, the Expert Committee of the Pharmaceutical R&D Strength Ranking, and the Organizing Committee of the 2023 China Pharmaceutical R&D Innovation Summit through a comprehensive statistical analysis of multiple R&D-related metrics for enterprises in 2022, including drug application and approval status, R&D investment, clinical trials, patent filings, and historical rankings of pharmaceutical R&D performance. The resulting ranking provides a more scientific and objective reflection and evaluation of companies’ overall R&D capabilities and innovative strength.
In recent years, Shijiazhuang Sihua Pharmaceutical Group, one of China’s top 100 pharmaceutical companies, has been driven by innovation, aligning its efforts with national strategic priorities and market demands. The company has boldly tackled critical “bottleneck” technologies, strategically expanding its portfolio across key therapeutic areas such as antivirals, antibacterials, anticancer agents, neurological disorders, cardiovascular diseases, gastroenterology, and anesthesia. It has coordinated the development and research of generic drugs, innovative medicines, specialty APIs, pharmaceutical packaging materials, and products undergoing consistency evaluation. Over the past two years in particular, benefiting from a comprehensive package of supportive policies at the national, provincial, and municipal levels, the company has steadily increased its R&D investment. Leveraging high-level innovation platforms—such as the enterprise technology center recognized by five national ministries and the National–Local Joint Engineering Laboratory—the group has partnered with renowned universities and research institutes, including China Pharmaceutical University, Zhengzhou University, Shenyang Pharmaceutical University, and the Chinese Academy of Medical Sciences. By bringing together leading pharmacological experts and academic leaders from both domestic and international circles, the company has established an innovation consortium led by itself, supported by universities and research institutions, and characterized by close collaboration among all relevant innovation stakeholders. This collaborative model continuously builds new competitive advantages, fosters a new development paradigm, and creates fresh opportunities for the company’s sustained growth. Since 2022, Shijiazhuang Sihua Pharmaceutical Group has consistently ranked among the industry leaders in China in terms of the number of approved and filed specialty generic drugs. Currently, nearly 200 projects are under development, spanning innovative medicines, high-end complex formulations, and specialty generics. The ongoing integration of talent, technology, and industrial chains is empowering the company to move up the value chain toward the mid- to high-end segments, ensuring robust and sustained growth.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091